Supplemental Figure S1: Prognostic impact of blastoid morphology, Ki67≥30%, MIPI and MIPI-c in patients included in the MCL2 and MCL3 trials. Kaplan-Meier estimates of OS, PFS and CIR according to the presence or absence of blastoid morphology (A-C), stratified according to Ki67 index above or below 30% (D-F), stratified by the MIPI index into low, intermediate and high-risk groups (G-I), and stratified by the combined MIPI, MIPI-c, into low (L), low-intermediate (LI), high-intermediate (HI) and high-risk (H) groups (J-L).
Supplemental Figure S2: Prognostic impact of CDKN2A deletions and NOTCH1 mutations on OS, PFS and CIR. Kaplan-Meier estimates of OS, PFS and CIR stratified by the presence or absence of CDKN2A deletions (A-C) and NOTCH1 mutations (D-F).